Healthcare

The interest is not purely speculative. In July 2026, fellow ASX-listed diagnostics group BCAL Diagnostics took a 10.2 per cent stake, and the company has installed a new chief executive tasked with sharpening its commercial focus. After a volatile few years, the central question …

The timing is deliberate. In a mid-December market update, CONNEQT Health told shareholders that Pulse sales had reached record levels in the December quarter, extending a run of commercial momentum that has coincided with a string of United States product awards. For a micro-cap …

The stock has attracted attention because it sits at the pivot point that decides most medtech stories: the shift from a single approved product to a repeatable, reimbursed commercial model. Progress so far looks encouraging, but the risks around adoption, funding and competition remain …

That progress has recast a business long defined by promise rather than revenue. The question for investors is whether a run of brand-name wins signals a genuine inflection, or simply encouraging early traction in a market where evaluations can take years to convert into …

The appointments come at a pivotal moment. Aroa has just delivered a record financial year and is preparing to launch Symphony, an outpatient soft-tissue product it believes can benefit from shifting US reimbursement dynamics. Whether the Auckland-headquartered group can convert that pipeline into durable, …

After years as a niche consumer-audio brand, Audeara is now leaning on wholesale channels, government-funded programs and white-label licensing to broaden its revenue base. The open question for the market is whether that groundwork translates into sustained, accelerating sales in the 2027 financial year, …

Mayne Pharma released preliminary results showing underlying earnings for FY26 fell 33 per cent (at the time of writing on 31 July 2026) to $31.7 million, while full-year revenue declined 6 per cent to $383.7 million. Gross profit was broadly flat at $248.2 million. …